The European Neuroendocrine Tumor Society (ENETS) guidelines specify that a pathological report of GEP-NENs should include morphology and differentiation on hematoxylin/eosin (HE) section, immunostaining for neuroendocrine markers by synaptophysin (Syn) and chromogranin A (CgA) and, once the neuroendocrine nature of the tumor is established, the proliferative activity must be assessed preferably by using Ki-67 staining [5]. Here, CGA is linked to neoplasm.